[ad_1]
South San Francisco, California, February 28, 2024–(BUSINESS WIRE)–Vistagen (Nasdaq: VTGN) is a biopharmaceutical company pioneering the field of neuroscience to deliver breakthrough treatments to individuals affected by psychiatric and neurological disorders. , the company announced today that company management will attend and host one-on-one meetings. TD Cowen 44th The annual healthcare conference will be held March 4-6, 2024 in Boston, Massachusetts.
TD Cowen 44th Annual Healthcare Conference
-
Chief Executive Officer Shawn Singh will provide an overview of the company on Wednesday, March 6, 2024, at 10:30 a.m. ET.
The webcast can be accessed through the Events page of the Investors section of the Company’s website at www.Vistagen.com. Investors interested in scheduling a one-on-one meeting during the conference should contact their Cowen representative.
About Vestagon
Vistagen (Nasdaq: VTGN) is a neuroscience biopharmaceutical company dedicated to delivering breakthrough treatments to individuals affected by psychiatric and neurological disorders. Vistagen’s five clinical-stage neuroscience drug candidates belong to a new class of drugs called pherines, which are investigational neuroactive nasal sprays with an innovative proposed mechanism of action that activates chemosensory neurons in the nasal passages to influence the brain basic neural circuits in the body without requiring systemic absorption or binding to receptors in the brain. Vistagen’s sixth investigational drug candidate is an oral prodrug with the potential to inhibit, but not block, NMDA receptor activity. At Vistagen, we are passionate about providing differentiated treatments and setting new standards of care for patients suffering from anxiety, depression and other neurological disorders. Please visit www.Vistagen.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240228708023/en/
contact method
investor:
Mark McPartland
(650)577-3606
markmcp@visagen.com
media:
Karen Scannell
(650)577-3601
cscannell@visagen.com
[ad_2]
Source link